Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera has responded to a jury decision favoring Guardant Health in a false advertising case from 2021. The litigation involved mutual claims regarding statements about Guardant's Reveal test. Natera disagrees with the verdict and plans to appeal. The company emphasizes that the case focused solely on comparative advertisements from 2021 and does not affect their Signatera test, which has become the leading MRD test in the U.S., supported by over 100 peer-reviewed publications.
Natera co-founder and executive chairman Matthew Rabinowitz has been named 2024 R&D Leader of the Year by R&D World. The organization recognized his pioneering work in genetic testing and precision medicine, particularly highlighting the development of transformational products including: Panorama™ for prenatal screening, Signatera™ for cancer recurrence detection, and Prospera™ for transplant rejection risk assessment. Dr. Rabinowitz, who served as CEO from 2005 to 2019, has authored numerous publications in prestigious journals and holds multiple patents in the field.
Natera has achieved a significant milestone with over 100 peer-reviewed publications on Signatera, its personalized molecular residual disease (MRD) test. The studies, published in prestigious journals like Nature and Journal of Clinical Oncology, demonstrate excellent clinical performance and utility. Signatera, the most widely used MRD test in the U.S., has served more than 200,000 cancer patients. The company continues to expand its research pipeline with several phase III randomized clinical trials across various cancer types.
Natera (NASDAQ: NTRA) reported Q3 2024 financial results, highlighting a 63.9% revenue increase to $439.8 million compared to Q3 2023. Product revenues surged by 64.4%. The company achieved a gross margin of 61.8%, up from 45.1% in the prior year. Natera processed approximately 775,800 tests, a 23.9% increase, and performed around 137,100 oncology tests, a 54.4% rise. The company reported a positive cash flow of $34.5 million and raised its annual guidance to $1.61-$1.64 billion in total revenue, 58%-61% gross margin, and $50-$75 million in net cash inflow.
Natera reported a net loss of $31.6 million ($0.26 per diluted share), an improvement from a $109.0 million net loss ($0.95 per diluted share) in Q3 2023. Total operating expenses increased by 34% to $311.1 million. The company held $922.3 million in cash and equivalents as of September 30, 2024, with total debt at $367.0 million. All convertible senior notes were redeemed or converted on October 11, 2024.
Natera (NASDAQ: NTRA) announced the completion of a study using Signatera from the CALGB (Alliance)/SWOG 80702 randomized, phase III clinical trial. This study evaluated the benefit of adding celecoxib to standard postoperative treatment FOLFOX in stage III colorectal cancer (CRC) patients. The analysis included 1,011 patients with post-surgical plasma samples, focusing on Signatera’s ability to identify a subgroup of patients who may benefit from celecoxib addition. Primary and secondary endpoints were disease-free survival (DFS) and overall survival (OS), respectively. Although celecoxib addition did not significantly improve DFS, NSAIDs like celecoxib have shown promise in benefiting certain CRC subpopulations. Results will be presented at the ASCO GI symposium in January 2024.
Natera (NASDAQ: NTRA), a leader in cell-free DNA and genetic testing, has announced its participation in three major healthcare investor conferences. The company will present at the UBS Global Healthcare Conference on November 14, the Wolfe Research Healthcare Conference on November 19, and the 36th Annual Piper Sandler Healthcare Conference on December 3. All presentations will be accessible via live webcast through Natera's investor relations website, with replays available after each event.
Natera, a global leader in cell-free DNA and genetic testing, has announced it will release its third quarter 2024 financial results on November 12, 2024, after market close. The company will host a conference call and webcast at 1:30 p.m. PT (4:30 p.m. ET) on the same day. Investors can access the call through domestic (1-888-770-7321) or international (1-929-201-7107) dial-in numbers using conference ID 7684785.
Natera (NASDAQ: NTRA) will present new data on its 385-gene kidney genetic test, Renasight™, at the American Society of Nephrology (ASN) Kidney Week 2024 in San Diego from Oct. 23-27. The company and collaborators will present 7 abstracts focused on comprehensive genetic testing for patients with chronic kidney disease (CKD).
This includes an updated analysis from the prospective RenaCARE study and additional data on the utility of genetic testing for CKD patients. The presentations align with recent support for renal genetic testing from organizations like NKF, KDIGO, and The New England Journal of Medicine.
Dr. Anthony Bleyer of Wake Forest University School of Medicine highlighted that 25% of dialysis patients don't know their kidney disease cause, emphasizing the importance of genetic testing. Natera's presentations will cover topics such as patient satisfaction with genetic counseling, genetic testing results in African American patients, and the genetic landscape of glomerular disease and FSGS.
Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA testing, has provided an update on its patent infringement litigation against NeoGenomics. On September 23, 2024, the District Court for the Middle District of North Carolina issued a permanent injunction against NeoGenomics' accused RaDaR assay, following a preliminary injunction from December 2023.
Natera is continuing to pursue its claim against a modified version of RaDaR for infringement of Natera's '454 patent. The company is seeking full remedies, including injunctive relief, especially after the Patent Office denied NeoGenomics' petition for 'inter partes' review challenging the validity of the '454 patent.
Natera (NASDAQ: NTRA) announced three new peer-reviewed publications for its Signatera test, surpassing 85 total publications. Key highlights include:
1. Colorectal cancer (CRC) data from the GALAXY arm of CIRCULATE-Japan, published in Nature Medicine and presented at ESMO 2024, showing Signatera's ability to predict overall survival and adjuvant chemotherapy benefit.
2. Additional CRC data from GALAXY, published in Annals of Oncology, demonstrating Signatera's ability to risk-stratify patients after liver metastases resection.
3. Breast cancer data from the BELLINI trial, published in Nature Medicine, exploring immune checkpoint inhibitors without chemotherapy in triple-negative breast cancer, with Signatera showing correlation to treatment response.